229 related articles for article (PubMed ID: 32650632)
1. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Improves Energetic Status and Cardiomyogenic Differentiation of Human Dilated Myocardium-Derived Primary Mesenchymal Cells.
Miksiunas R; Rucinskas K; Janusauskas V; Labeit S; Bironaite D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650632
[TBL] [Abstract][Full Text] [Related]
2. Cardiomyogenic Differentiation Potential of Human Dilated Myocardium-Derived Mesenchymal Stem/Stromal Cells: The Impact of HDAC Inhibitor SAHA and Biomimetic Matrices.
Miksiunas R; Aldonyte R; Vailionyte A; Jelinskas T; Eimont R; Stankeviciene G; Cepla V; Valiokas R; Rucinskas K; Janusauskas V; Labeit S; Bironaite D
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884505
[TBL] [Abstract][Full Text] [Related]
3. Cardiomyogenic Differentiation of Human Dental Follicle-derived Stem Cells by Suberoylanilide Hydroxamic Acid and Their
Sung IY; Son HN; Ullah I; Bharti D; Park JM; Cho YC; Byun JH; Kang YH; Sung SJ; Kim JW; Rho GJ; Park BW
Int J Med Sci; 2016; 13(11):841-852. PubMed ID: 27877076
[TBL] [Abstract][Full Text] [Related]
4. The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes.
Bocchi L; Motta BM; Savi M; Vilella R; Meraviglia V; Rizzi F; Galati S; Buschini A; Lazzaretti M; Pramstaller PP; Rossini A; Stilli D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31014028
[TBL] [Abstract][Full Text] [Related]
5. Trichostatin a promotes cardiomyocyte differentiation of rat mesenchymal stem cells after 5-azacytidine induction or during coculture with neonatal cardiomyocytes via a mechanism independent of histone deacetylase inhibition.
Yang G; Tian J; Feng C; Zhao LL; Liu Z; Zhu J
Cell Transplant; 2012; 21(5):985-96. PubMed ID: 21944777
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid promotes cardiomyocyte differentiation of rat mesenchymal stem cells.
Feng C; Zhu J; Zhao L; Lu T; Zhang W; Liu Z; Tian J
Exp Cell Res; 2009 Oct; 315(17):3044-51. PubMed ID: 19445929
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication.
Saha B; Parks RJ
J Virol; 2019 Jun; 93(12):. PubMed ID: 30944181
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibition destabilizes the multi-potent state of uncommitted adipose-derived mesenchymal stromal cells.
Dudakovic A; Camilleri ET; Lewallen EA; McGee-Lawrence ME; Riester SM; Kakar S; Montecino M; Stein GS; Ryoo HM; Dietz AB; Westendorf JJ; van Wijnen AJ
J Cell Physiol; 2015 Jan; 230(1):52-62. PubMed ID: 24912092
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibition induces autophagy and mitochondrial biogenesis to maintain mitochondrial homeostasis during cardiac ischemia/reperfusion injury.
Yang J; He J; Ismail M; Tweeten S; Zeng F; Gao L; Ballinger S; Young M; Prabhu SD; Rowe GC; Zhang J; Zhou L; Xie M
J Mol Cell Cardiol; 2019 May; 130():36-48. PubMed ID: 30880250
[TBL] [Abstract][Full Text] [Related]
11. The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism.
Moore JB; Zhao J; Keith MC; Amraotkar AR; Wysoczynski M; Hong KU; Bolli R
Stem Cells; 2016 Dec; 34(12):2916-2929. PubMed ID: 27501845
[TBL] [Abstract][Full Text] [Related]
12. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma.
Carbajo-García MC; García-Alcázar Z; Corachán A; Monleón J; Trelis A; Faus A; Pellicer A; Ferrero H
Fertil Steril; 2022 Feb; 117(2):433-443. PubMed ID: 34809976
[TBL] [Abstract][Full Text] [Related]
14. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibition is cytotoxic to oligodendrocyte precursor cells in vitro and in vivo.
Dincman TA; Beare JE; Ohri SS; Gallo V; Hetman M; Whittemore SR
Int J Dev Neurosci; 2016 Nov; 54():53-61. PubMed ID: 27587342
[TBL] [Abstract][Full Text] [Related]
16. In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
Tambunan US; Bramantya N; Parikesit AA
BMC Bioinformatics; 2011; 12 Suppl 13(Suppl 13):S23. PubMed ID: 22373132
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
18. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Angiotensin II, Retinoic Acid, EGCG, and Vitamin C on the Cardiomyogenic Differentiation Induction of Human Amniotic Fluid-Derived Mesenchymal Stem Cells.
Gasiūnienė M; Valatkaitė E; Navakauskaitė A; Navakauskienė R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228183
[TBL] [Abstract][Full Text] [Related]
20. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
